Appointment of Associate Faculty Member at Sanger Institute
News Apr 08, 2013
MISSION Therapeutics (“MISSION”) has announced the recent appointment of the Company’s co-founder and Chief Scientific Officer, Professor Steve Jackson as Associate Faculty Member at the prestigious Wellcome Trust Sanger Institute.
Professor Jackson is a Fellow of both the Royal Society and the UK Academy of Medical Sciences, and since 1995 has held the Frederick James Quick Chair of Biology at the University of Cambridge, a post which he currently combines with Head of the Cancer Research UK Laboratories at the Gurdon Institute, Cambridge.
Professor Jackson takes a position within the Department of Human Genetics at the Sanger Institute, where his research will focus on the maintenance of genome stability.
His research group based at the Gurdon Institute, University of Cambridge and the new complementary group at the Sanger Institute are focused on the mechanistic understanding of DNA repair and damage responses in normal and diseased cells.
His Maintenance of Genome Stability team at the Sanger Institute will aim to understand precisely how cells respond to DNA damage.
This research will provide new insights into human cell biology and human disease, and may identify opportunities for developing new diagnostic tools and therapeutic agents.
The post of Associate Faculty Member gives Professor Jackson access to the world class research of the Sanger Institute, allowing his research teams to collaborate with other Sanger Institute researchers and draw on the wealth of resources within the Institute, particularly in cancer genetics.
"We are delighted to welcome such a distinguished basic and translational researcher as Steve Jackson to our Associate Faculty - a cadre of researchers whose skills complement our own and with whom we can build new opportunities for genomic exploration," says Professor Michael Stratton, Director of the Wellcome Trust Sanger Institute.
Professor Stratton continued, “Our collective aim is to build a portfolio of research that will contribute as rapidly as possible to therapeutic development and we very much look forward to achieving that goal with Steve.”
Dr Michael Moore, Chairman of the MISSION Board commented: “Steve’s appointment to the Associate Faculty position at the Sanger Institute is further testimony to his distinction and leadership position as a world-class scientist in the field of cancer genetics and of DNA repair. Steve’s contribution to the elucidation of disease mechanisms contributing to cancer and other disorders will stimulate the pursuit of new and more effective diagnostic and therapeutic approaches.”
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic LeukemiaNews
TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.READ MORE
Comments | 0 ADD COMMENT
Theme: Gathering the Newborn Advances in Cardiology
Mar 19 - Mar 20, 2018
11th International Conference on Cancer Stem Cells
Jun 11 - Jun 13, 2018